
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dialysis
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SAfety of Regional Citrate Anticoagulation (SARCA Study)
Details : Dialysis is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Kidney Injury.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : Dialysis
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcium Acetate
Therapeutic Area : Nephrology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules
Details : Calcium Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hyperphosphatemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2014
Lead Product(s) : Calcium Acetate
Therapeutic Area : Nephrology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glucose
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Glucose is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 20, 2012
Lead Product(s) : Glucose
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Study Phase : Phase III
Recipient : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sucroferric Oxyhydroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2011
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Recipient : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcium Acetate
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calcium Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 02, 2011
Lead Product(s) : Calcium Acetate
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Study Phase : Phase III
Recipient : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sucroferric Oxyhydroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2011
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Recipient : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety Study of Pentoxifylline for the Treatment of Anemia
Details : Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 13, 2010
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All